spacer
home > epc > summer 2002 > making the right choice in pharmaceutical outsourcing
PUBLICATIONS
European Pharmaceutical Contractor

Making the Right Choice in Pharmaceutical Outsourcing

Outsourcing of analysis within the pharmaceutical industry has steadily increased in recent years and this trend seems set to continue with estimated growth being as high as 9 per cent per annum.

Key reasons for outsourcing analysis include:

Little or no facilities in-house

Utilisation of internal competence on higher value return science, such
as better value for money from internal staff

In-house capacity problems due to increased testing in line with regulations

The problem of choosing the right outsourcing partner has been exacerbated by the growth in the number of contract service organisations (CSOs) on the market. Often these organisations appear to offer similar services and returns for the customer - thus making the partnering decision difficult.

This article will explore four key areas worthy of consideration when selecting your outsourcing laboratory.

Balancing Cost and Confidence

When faced with the prospect of outsourcing you must be convinced of the viability and robustness of your decision to hand over control of a project to a third party. As the project manager, you must be confident about getting value for money, quality and delivery from your outsourcing partner.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Brian Arnot, Business Development Executive at Tepnel Scientific Services

Brian Arnot is an experienced Analytical Chemist who has worked in the contract analytical services sector since 1984.

More recently, he has joined the business development team of Tepnel Scientific Services (formerly the Medicines Testing Laboratory), where he is responsible for the development of core business activities in both the UK and Europe.

spacer
Brian Arnot
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

[Noáin, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
More info >>

White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement